Noah Medical

Executive Summary

Noah Medical is a Silicon Valley-based medical robotics company developing an intelligent platform for early lung cancer diagnosis. Its flagship product, the Galaxy System, integrates advanced imaging and robotic bronchoscopy with proprietary Tool-in-Lesion Tomography (TiLT+) technology, aiming to significantly improve biopsy accuracy and diagnostic yield. Lung cancer remains the leading cause of cancer deaths, largely due to late detection; Noah's technology seeks to enable earlier, more precise diagnosis to improve patient survival rates. The company is positioned at the intersection of medical devices, oncology, and digital health, leveraging robotics and AI to address a critical unmet need in pulmonology. Founded in 2025 (with likely earlier stealth operations), Noah Medical has attracted top talent from the robotics and medical device industries. While specific funding details are undisclosed, the company has likely secured significant venture capital to support its development and regulatory pathway. As a private, pre-commercial entity, Noah's near-term focus is on obtaining regulatory clearance for the Galaxy System and generating clinical evidence to support adoption. Its innovative TiLT+ technology differentiates it from competitors like Auris Health and Intuitive, positioning it as a potential leader in the lung biopsy market. With a strong value proposition and clear clinical need, Noah Medical represents a compelling opportunity in early-stage medtech.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Galaxy System60% success
• Q2 2026Publication of Clinical Study Results in Peer-Reviewed Journal70% success
• Q4 2026Strategic Partnership with Major Hospital Network or Diagnostics Company50% success